Loading clinical trials...
Loading clinical trials...
Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)
Conditions
Interventions
Adagrasib
Anti-PD-L1 Monoclonal Antibody
+12 more
Locations
13
United States
CTCA at Western Regional Medical Center
Goodyear, Arizona, United States
City of Hope Corona
Corona, California, United States
City of Hope Medical Center
Duarte, California, United States
City of Hope Seacliff
Huntington Beach, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
City of Hope Antelope Valley
Lancaster, California, United States
Start Date
April 8, 2026
Primary Completion Date
October 8, 2028
Completion Date
October 8, 2028
Last Updated
April 15, 2026
NCT06498635
NCT06660407
NCT06500455
NCT03191149
NCT06349642
NCT06122064
Lead Sponsor
City of Hope Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions